Physician profile
Douglas C Decker
NPI 1629096128
$2,321.16
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.97 · 2020: $55.81 · 2021: $296 · 2022: $266 · 2023: $192 · 2024: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,400 · Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,400.00 |
| Food and Beverage | $290.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,400.00 | 2024 | |
| Abbvie INC. | $358.42 | 2020-2023 | Liletta, Orilissa |
| Mayne Pharma Commercial LLC | $178.59 | 2021-2023 | |
| Hologic Sales and Service, LLC | $99.33 | 2022-2024 | Aptima |
| Organon LLC | $71.97 | 2021-2023 | Nexplanon |
| Therapeuticsmd, INC. | $58.53 | 2020-2021 | |
| Exeltis, USA INC. | $36.92 | 2020-2022 | |
| Agile Therapeutics, INC. | $31.12 | 2021-2022 | |
| Biogen, INC. | $24.24 | 2024 | Vumerity |
| Coopersurgical, INC. | $21.02 | 2022 | |
| Alfasigma USA, INC. | $15.05 | 2021 | |
| Evofem Biosciences, INC. | $14.00 | 2021 | |
| Minerva Surgical, INC | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.